RSRachel Stemme

Rachel Stemme

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rachel Stemme has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Association Between Post‐Kidney Transplant Persistent Hyperparathyroidism and Fracture Risk: A Longitudinal Cohort Study

    by Rachel Stemme, Yi Liu, Jingyao Hong, Yiting Li, Joy Zhou Done, Jennine Weller, Anatoliy V. Rudin, Daniel C. Brennan, Lilah F. Morris‐Wiseman, Dorry L. Segev, et al.

    Introduction: Hyperparathyroidism (HPT) commonly persists following kidney transplant (KT) and can result in bone alterations. However, the association between persistent HPT post‐KT and fracture risk is not well‐understood. We sought to quantify the association between persistent HPT at 1‐year post‐KT and fracture risk among KT recipients. Methods: We leveraged a longitudinal prospective cohort of 344 adult KT recipients who underwent KT at a single institution (12/2008–07/2019). PTH levels were retroactively abstracted, and fractures after 1‐year‐post‐KT were ascertained using ICD‐9/ICD‐10 codes. Competing risk models were used to estimate the association between persistent HPT (PTH ≥ 70 pg/mL) at 1‐year post‐KT and the risk of fracture, with death treated as a competing event. Results: Among 344 KT recipients, 227 (66.0%) had persistent HPT at 1‐year post‐KT. After adjusting for confounders, HPT 1‐year after KT was associated with a 3.11‐fold increased risk of fractures (95% CI: 1.08–8.91). There were no differences in this association by age, sex, race, eGFR at 1‐year‐post‐KT, osteoporosis at KT, or dialysis vintage. Conclusion: Recipients with HPT 1‐year after KT had a significantly higher risk of fractures than those without persistent HPT. Future studies should establish standardized practice guidelines for the treatment of persistent HPT to mitigate fracture‐related morbidity and mortality.


  • Higher Distressed Communities Index is associated with more aggressive features in papillary thyroid cancer

    by Joy Zhou Done, Alexandra Helbing, Rachel Stemme, Darci Foote, Jennine Weller, Mingzhao Xing, Lilah F. Morris-Wiseman, Aarti Mathur


  • Financial Toxicity Across the Thyroid Cancer Care Continuum: A Systematic Review

    by Maria Armache, Rachel Stemme, Wassim Najjar, Nadia L. Samaha, Madison Hearn, Stefany Lazieh, Emily Joseph, Kaitlyn Frazier, Douglas Ball, Jonathon O. Russell, et al.

    Objective: To describe the financial toxicity (FT) associated with thyroid cancer (TC) across the care continuum and elucidate factors contributing to FT in this patient population.Data Sources: PubMed, Embase, Cochrane, Web of Science, and Scopus.Review Methods: A systematic review was conducted of peer‐reviewed studies on FT in patients with a history of TC, between 1995 and 2024, using search terms “thyroid cancer,” “financial toxicity,” and their relevant synonyms. Full‐text, English‐language studies reporting subjective (self‐reported FT) and objective (out‐of‐pocket [OOP], employment changes, and bankruptcy) FT outcomes were included.Results: A total of 927 studies were identified, with 13 meeting the inclusion criteria. Nine studies addressed subjective FT, with prevalence rates ranging from 16% to 47%. Younger age, lack of health insurance, belonging to a racial minority, and having a lower annual household income were significantly associated with increased FT. Patients with TC had higher OOP costs and bankruptcy rates compared to other cancer types or matched controls.Conclusion: Despite a generally favorable prognosis, patients with TC experience significant FT, particularly among vulnerable groups such as younger individuals, the uninsured, and racial/ethnic minorities. In the setting of the rising incidence of TC, it is essential to identify and address FT in this population. Addressing FT requires a multifaceted approach, which includes incorporating financial counseling and cost discussions in routine care, ensuring comprehensive insurance coverage, and implementing employer‐level protections to mitigate income and insurance loss. Further research is needed to understand the potential financial implications of different care pathways in the treatment of TC.


  • Screening for Financial Toxicity Among Patients With Cancer: A Systematic Review

    by Nadia L. Samaha, Leila J. Mady, Maria Armache, Madison Hearn, Rachel Stemme, Reshma Jagsi, Laila A. Gharzai